Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is ...

Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

Pfizer has gained accelerated approval from the US FDA for BRAFTOVI in conjunction with cetuximab and mFOLFOX6 for treating mCRC.

A community meeting organized by Easton council members to allow residents to hear more about a massive warehouse project ...

Pfizer on Tuesday said it does not expect the Trump administration to make major changes to vaccine policy next year even as ...

On Thursday, Pfizer Inc (PFE) stock saw a decline, ending the day at $25.77 which represents a decrease of $-0.12 or -0.46% from the prior close of $25.89. The stock opened at $25.7 and touched a low ...

Pfizer stock has been weighed down lately, amid falling revenues and margins. The demand for the Covid-19 vaccine has taken a hit in recent years and the company has been looking to bridge the revenue ...

Pfizer Inc. (NYSE:PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance. Ahead of the ...

Despite today’s strength, Pfizer shares are trading deep in a long-term bear market trend. The stock crossed into bearish ...

Pfizer on Tuesday forecast 2025 profit roughly in line with estimates, offering some relief to investors after the drugmaker ...

Pfizer shares rallied after the drugmaker's 2025 guidance met Wall Street expectations, cheering shareholders as the ...

Pfizer shares rose Tuesday morning after the pharmaceutical company affirmed its full-year 2024 projections and issued 2025 ...